Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Equity Ratio: 2021-2025

Historic Equity Ratio for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to 0.92.

  • Krystal Biotech's Equity Ratio rose 1.75% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year increase of 1.75%. This contributed to the annual value of 0.90 for FY2024, which is 5.80% down from last year.
  • As of Q3 2025, Krystal Biotech's Equity Ratio stood at 0.92, which was up 0.38% from 0.91 recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Equity Ratio ranged from a high of 0.97 in Q1 2021 and a low of 0.89 during Q1 2022.
  • Moreover, its 3-year median value for Equity Ratio was 0.92 (2025), whereas its average is 0.93.
  • The largest annual percentage gain for Krystal Biotech's Equity Ratio in the last 5 years was 3.67% (2022), contrasted with its biggest fall of 8.52% (2022).
  • Over the past 5 years, Krystal Biotech's Equity Ratio (Quarterly) stood at 0.95 in 2021, then decreased by 1.33% to 0.94 in 2022, then rose by 1.75% to 0.95 in 2023, then fell by 5.80% to 0.90 in 2024, then climbed by 1.75% to 0.92 in 2025.
  • Its Equity Ratio was 0.92 in Q3 2025, compared to 0.91 in Q2 2025 and 0.92 in Q1 2025.